Skip to content
The Policy VaultThe Policy Vault

Xalkori (crizotinib) — Medica

Melanoma with ALK or ROS1 fusions

Initial criteria

  • age ≥ 18 years
  • EITHER disease has anaplastic lymphoma kinase (ALK) fusion OR disease has ROS1 fusion

Approval duration

1 year